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Cardiovascular disease (CVD) is the leading cause of death in the world. Arrhythmia is a type 
of CVD which can be caused by store overload induced calcium (Ca2+) release (SOICR) in 
cardiomyocytes. SOICR occurs through the cardiac ryanodine receptor (RyR2). RyR2 
phosphorylation is known to be a cause of SOICR. Patients with diabetes (DM) have an 
increased risk of arrhythmia as well as an increase in RyR2 phosphorylation by certain kinases. 
One kinase activated in DM is Protein Kinase C (PKC). PKC isoforms; α, ε, β2 and δ have an 
increased activity in the DM heart. Our study aimed to determine the effect of PKC on RyR2 
in regard to SOICR. We hypothesised that activation or overexpression of PKC would result in 
an increase in SOICR consistent with RyR2 phosphorylation by other kinases. SOICR was 
examined in HEK293 cells expressing RyR2 with or without PKC overexpression in the 
presence and absence of a PKC activator (Dic8) and inhibitor (Go6983). Dic8, as well as 
Go6983, resulted in an increase in the occurrence of SOICR. Recent studies in the lab show 
that ATP analogues directly affect RyR2 resulting in SOICR, making the results of Go6983 
hard to interpret. Overexpression of PKCα, with or without Dic8, resulted in small increase in 
the occurrence of SOICR. However, overexpression of PKCε, with or without Dic8, resulted in 
a large increase in the occurrence of SOICR. The propensity for SOICR is determined by the 
sensitivity of RyR2 to sarcoplasmic reticulum (SR) Ca2+. To study if PKC altered the sensitivity 
of RyR2 to SR Ca2+ a SR targeted Ca2+ sensing protein, D1ER, was used. Overexpression of 
PKCα resulted in no change in the sensitivity of RyR2 to SR Ca2+, however, consistent with the 
increase in the propensity for SOICR, PKCε resulted in an increase in the sensitivity of RyR2 
to SR Ca2+. Our data indicate that akin to other kinases, PKCε can increase SOICR through the 
RyR2 due to an increase in RyR2’s sensitivity to SR Ca2+. These findings may represent a novel 
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Diabetes mellitus (DM) is a disease characterised by hyperglycemia, and is clinically diagnosed 
as a fasting blood plasma glucose level ≥7.0 mmol/L (Zimmet et al., 2001). There are two types 
of DM; type 1, a T-lymphocyte autoimmune disease which accounts for approximately 10% of 
all DM, and type 2 a metabolic disorder which accounts for approximately 90% of all DM 
(Zimmet et al., 2001). The worldwide prevalence of DM has almost doubled from 1980 (4.7%) 
to 2014 (8.5%) and is still on the rise (NCD Risk Factor Collaboration, 2016). In 2014, it was 
estimated 3.7 million deaths were attributed to DM worldwide where over 50% were 
cardiovascular disease (CVD) related (NCD Risk Factor Collaboration, 2016). 
 
1.1.1 Diabetic Heart Disease  
Patients with DM are known to have many CVD’s, including; microangiopathy, 
macroangiopathy, cardiomyopathy, and arrhythmias, all of which are related due to many 
molecular and biochemical changes that can occur in hyperglycemic environments (Grundy et 
al., 1999). Diabetic micro/macro-angiopathy has been well described in the literature, as most 
DM patients will experience some form of vessel dysfunction, which can result in retinopathy, 
nephropathy, or neuropathy (Alonso-Moran et al., 2014). In addition to vessel disease, one 
epidemiological study comparing 293,124 DM against 552,624 non-DM hospitalized patients, 
between the years 1990 and 2000, showed an increase in the percent occurrences of atrial 
fibrillation (AF) and atrial flutter (AFL) in DM compared to the non-DM (14.9% versus 10.3%, 
and 4% versus 2.5%, respectively) (Movahed et al., 2005). The increased association and risk 
of arrhythmia in DM patients increases the risk of heart failure and death in these patients 
(Siscovick et al., 2010).  
2 
 
1.2 Contraction of the Heart 
1.2.1 Heart Conduction 
The heart beats due to spontaneous electrical activity generated by cardiac pacemaker cells 
(CPCs) in the sinoatrial (SA) node, located in the upper region of the right atrium (RA).  CPCs 
in the SA node generate a wave of electrical activity which propagates down towards the 
atrioventricular (AV) node, located in the lower region of the RA (Figure 1.1). Here, the wave 
of electrical activity is then sent down the bundle of His fibres which are located within the 
intraventricular septum, before moving through the Purkinje fibres which are located around 
the walls of the left and right ventricular walls (Figure 1.1). Electrical stimulation of 
cardiomyocytes results in a coordinated contraction of the myocardium, as cardiomyocytes are 
all connected by intercalated discs that contain desmosomes (physical connection) and gap 
junctions (electrical connection) (Saffitz, 2005). This process results in rhythmic contraction 
and relaxation of the heart. 
 
 
Figure 1.1 Conduction of the Heart. 
CPCs in the SA node send electrical activity that propagates down to the AV node followed by 
the Bundle of His then through the Purkinje fibres in the left and right ventricles. Adapted from 
Wiley et al., 2011. 
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1.2.2 Excitation-Contraction Coupling  
The propagating electrical signal must be converted to a chemical one to drive contraction; this 
process is known as excitation-contraction coupling (Sandow, 1952). Electrical activity 
generated by the pacemaker cells in the heart described in Section 1.2.1, results in a change in 
the membrane potential at the level of cardiomyocytes resulting in the opening of voltage-gated 
L-type calcium (Ca2+) channels on the plasma membrane (PM), slightly raising the tightly 
regulated Ca2+ concentration in the cytosol (Figure 1.2) (Aronsen et al., 2013). This slight Ca2+ 
increase activates the ryanodine receptor 2 (RyR2), which is a Ca2+ release channel located on 
the sarcoplasmic reticulum (SR) membrane (Figure 1.2) (Zhang et al., 2015). Activation of the 
RyR2 causes a large amount of Ca2+ to be released into the cytosol from the SR, a process 
termed Ca2+ induced Ca2+ release (CICR), which is sufficient for contraction of the heart (Figure 
1.2) (Aronsen et al., 2013). The high Ca2+ concentration in the cytosol is then either recycled 
into the SR by the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) or extruded out of the 
cell through the Na+ Ca2+ exchanger (NCX) or the PM Ca2+ ATPase (PMCA) channel, to 
prepare for the sequential contraction of the heart (Figure 1.2) (Eisner et al., 2013).  
 
Figure 1.2 Excitation Contraction Coupling. 
The opening of the LTCC after depolarisation of the PM allows for Ca2+ entry into the 
cardiomyocyte. Ca2+ activates the RyR2 allowing for CICR from the SR. Ca2+ binds to the 
myofilament allowing for contraction of the cell. Ca2+ is then recycled into the SR via SERCA 




Cardiac arrhythmia is a CVD characterised by an irregular heartbeat, which can be clinically 
diagnosed using electrocardiography, where any changes in the normal conduction of the heart, 
described in Section 1.2.1, is considered cardiac arrhythmia (Grace & Roden, 2012). There are 
many factors that can cause arrhythmia, however, one underlying factor is the disruption of 
Ca2+ handling proteins in cardiomyocytes (Wagner et al., 2015). In particular, an increased 
activity of the RyR2 can result in arrhythmia due to spontaneous Ca2+ leak from the SR (Jones 
et al., 2008). The clinical implications of arrhythmia can vary from mild outcomes, such as 
reducing the quality of life, to severe outcomes including sudden cardiac death (Grace & Roden, 
2012).  
 
1.3.1 Store Overload Induced Ca2+ Release 
Modification of Ca2+ handling proteins involved in CICR; including RyR2, PLB, and SERCA 
mentioned in Section 1.2.2, have been attributed to the un-stimulated leak of Ca2+ from the SR 
(Aschar-Sobbi et al., 2012; Shan et al., 2012). The un-stimulated Ca2+ release is referred to as 
spontaneous Ca2+ release, or due to its dependence on SR Ca2+ levels, store overload-induced 
Ca2+ release (SOICR) (Belke et al., 2004; Jones et al., 2008). Normally the SR is never filled 
to maximum, rather it has a certain level of Ca2+ within the store (Figure 1.3 A) (Jones et al., 
2008). If the Ca2+ level within the SR increases and surpasses a certain release threshold or 
SOICR threshold, it results in the activation of the RyR2 resulting in SOICR. The amount of 
Ca2+ released from the SR is determined by the termination of SOICR (termination threshold) 
(Palade et al., 1983). Modifications of RyR2 can result in the reduction of this Ca2+ release 
threshold in the SR, below the SR Ca2+ load which then can cause SOICR seen in Figure 1.3 B. 
Modifications of PLB and SERCA can result in SOICR due to overloading Ca2+ levels within 
the SR, surpassing the Ca2+ release threshold (Jones et al., 2008). RyR2 modifications can also 
5 
 
result in a reduction in the termination threshold, resulting in an increased amount of Ca2+ every 
time RyR2 is activated seen in Figure 1.3 C (Tang et al., 2012). A reduction of termination 
threshold does not result in SOICR, however, the combination of reduced termination threshold 
along with release threshold would result in an increased occurrence of SOICR along with a 
high amount of Ca2+ leak resulting in elevated cytosolic Ca2+ levels, Figure 1.3 D.  
 
 
Figure 1.3 SOICR. 
(A) The SR is filled with a certain level of Ca2+ (blue) where if this level would increase over 
the SOICR threshold it would result in SOICR. After activation of the RyR2 in CICR, only a 
proportion of Ca2+ is released to ensure the SR does not get emptied completely. (B) 
Modification of the RyR2 can result in a reduction of the SOICR threshold, increasing the 
occurrence of SOICR. (C) Modification of RyR2 can result in a reduction in termination of 
SOICR, releasing a higher proportion of Ca2+ when activated. (D) A combination of a decreased 
SOICR threshold and termination of SOICR results high a large SOICR event. Created with 
Microsoft PowerPoint. 
 
As Ca2+ levels are tightly regulated in the cytosol of cardiomyocytes, an increase in Ca2+ release 
due to SOICR must be adequately removed by an increase of SERCA or the NCX activity. An 
increase in SERCA activity is not effective at reducing the Ca2+ levels, as an increased uptake 
of Ca2+ into the SR would result in a sequential SOICR event. As a result, the high amounts of 
Ca2+ in the cytosol must be extruded by increased activity of NCX (Venetucci et al., 2007). 
NCX is effective at maintaining the Ca2+ levels during SOICR events, however, because it is 
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an electrogenic exchanger, one Ca2+ ion out of the cytosol into the extracellular space for three 
Na+ ions from the extracellular space into the cytosol, removal of high amounts of Ca2+ results 
in an elevated level of Na+ within the cytosol (Venetucci et al., 2007). An increase of cations 
within the cytosol causes an increase in the membrane potential, which can then result in the 
depolarization of the cardiomyocyte membrane, considered as delayed after depolarisation 
(DAD) (Bers, 2002; Belke et al., 2004; Venetucci et al., 2007). If there are enough 
cardiomyocytes experiencing DAD’s, the electrical depolarization can be propagated 
throughout the whole heart due to the electrical connection between the cardiomyocytes 
(Saffitz, 2005). The occurrence of these DAD’s throughout the whole heart leads to contraction 
of the heart, in the absence of a pacemaker depolarization wave, resulting in arrhythmia 
(Houser, 2000).  
 
1.3.2 RyR2 Modifications 
RyR is a homo-tetrameric protein and is the largest known ion channel (2.2MDa) and exists as 
three isoforms, RyR1, RyR2 and RyR3, where RyR2 is mainly expressed in cardiomyocytes 
(Bers, 2004; Van Petegem, 2015). The RyR2 monomer is made up of approximately 5,000 
amino-acids, therefore it is proposed and expected that there are many potential sites for post-
translational modifications including; phosphorylation, oxidation, and glycation (Jones et al., 
2008; Van Petegem, 2015). Under normal physiological conditions, the RyR2 is 
phosphorylated at a basal level, however, in pathophysiological conditions where kinases such 
as Ca2+/calmodulin-dependant protein kinase II (CaMKII) and protein kinase A (PKA) are 
overexpressed or excessively active, the RyR2 is hyperphosphorylated (Wehrens et al., 2006). 
Although there are predicted to be many phosphorylation residues within RyR2, only three 
phosphorylation residues have been reported to date; serine (S) 2808, S2814 and S2030, all of 
which have been studied extensively for CaMKII and PKA (Figure 1.4) (Huke & Bers, 2008; 
Valdivia, 2012). CaMKII and PKA are kinases that phosphorylate serine/threonine residues and 
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are normally auto-inhibited due to their respective regulatory domain blocking the catalytic 
sites of the kinase (Zhang et al., 2012; Erickson, 2014). There is a large debate on the functional 
effect of phosphorylation of these three RyR2 residues; however, intracellular Ca2+ imaging, 
when hyperphosphorylated at Serine 2808, shows Ca2+ leak (Fischer et al., 2015). It is proposed 
that hyperphosphorylation of the RyR2 can result in a reduction in the release threshold, causing 
SOICR events, which is linked to arrhythmias (Xiao et al., 2007). Because many kinases 
phosphorylate serine/threonine residues, an abundance of serine and threonine residues within 
RyR2 make it plausible to assume that there may be many other kinases and phosphorylation 
sites that could affect the activity of RyR2.  
 
Figure 1.4 RyR2 – Multi-phosphorylation Site Model. 
Proposed model of RyR2 showing a specific phosphorylation “hot spot”. Within this “hot spot” 
serine 2808, 2811 and 2814 are proposed to be able to be phosphorylated by PKA and CaMKII. 
Image taken from (Valdivia, 2012).  
 
As mentioned, pathophysiological conditions can result in an increased activity of kinases 
including CaMKII and PKA. Acute hyperglycemic environments have shown to cause the 
addition of O-linked glycosylation at the serine 279 region of CaMKII (Erickson et al., 2013). 
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This O-linked glycosylation modification of CaMKII results in overactivation of the kinase, 
leading to spontaneous Ca2+ release from the SR, which had been also linked with 
arrhythmogenesis (Erickson et al., 2013). Similarly, the hyperglycaemic environment in DM 
increases the production of diacylglycerol (DAG) an agonist for protein kinase C (PKC) (Xia 
et al., 1994). PKC and protein kinase G (PKG) are two other kinases that have been shown to 
be able to phosphorylate the RyR2, although their effect and the residues targeted are unknown 
(Takasago et al., 1991). 
 
1.4 PKC 
PKC is a family of kinases that can regulate the activity of proteins via phosphorylation of 
hydroxyl groups on serine or threonine amino acid residues (Newton, 2003). The PKC family 
contains 15 different isoforms within humans, all of which are divided into 3 separate 
subfamilies based on their activation requirements; conventional (cPKC), novel (nPKC) and 
atypical (aPKC) (Newton, 2003). PKC’s function has been well described in cell proliferation, 
cell survival and cell apoptosis, where changes in PKC expression have been linked to many 
diseases including cancer, Alzheimer’s disease and DM (Hongpaisan et al., 2011; Liao et al., 
2013; Maurya & Vinayak, 2015). In the heart, PKC has been shown to be involved in 
myocardial infarction, acute reperfusion injury, compensatory hypertrophy and vascular 
dysfunction (Braz et al., 2004; Mochly-Rosen et al., 2012; Newton et al., 2016). Western blot 
analysis shows that within a rat heart, PKC isoforms; α, β2, δ, ε and γ are expressed, with PKCα 
as the most expressed isozyme in the human heart (Borghini et al., 1994; Ping et al., 1997; 




1.4.1 Structure of PKC  
All PKC isoforms contain a regulatory domain connected to a catalytic domain via a hinge 
region (Geraldes & King, 2010; Steinberg, 2012). Among all three subfamilies of PKC, the 
catalytic domain is conserved (Geraldes & King, 2010; Steinberg, 2012). The catalytic domain 
contains a C3 region, specific for ATP binding and a C4 region, for substrate binding (Figure 
1.5) (Geraldes & King, 2010; Steinberg, 2012). Within the regulatory domain is a 
pseudosubstrate region, which contains a small amino acid sequence that binds and inhibits the 
catalytic domain (Geraldes & King, 2010; Steinberg, 2012). The subfamilies differ in the 
regulatory domain. cPKC and the nPKC subfamilies contain a C1 region within the regulatory 
domain, for the binding of DAG (Figure 1.5) (Geraldes & King, 2010). cPKC is the only 
subfamily with a C2 region that has a Ca2+ binding/sensor (Figure 1.5) (Geraldes & King, 2010).  
 
 
Figure 1.5 Structure of PKC isoforms. 
cPKC, nPKC, and aPKC contain a regulatory domain connected to the catalytic domain via the 
hinge region. In cPKC’s, the regulatory domain contains a C1 region for DAG binding and a 
C2 region for Ca2+ binding to activation of the kinase. In nPKC’s, the regulatory domain 
contains a C1 region for DAG binding for activation of the kinase. In aPKC’s, the regulatory 
domain contains a PB1 region for phosphatidylinositols binding for activation of the kinase. 
The catalytic domain containing a C3, ATP binding region and a C4, substrate binding region. 
Pseudosubstrate within the regulatory domain region inhibits the catalytic domain in all 3 sub-




1.4.2 Activation of PKC 
cPKC’s and nPKC’s can both be activated by G-protein coupled receptor αq (GPCR-αq) 
activation (Figure 1.6) (New & Wong, 2007). When the correct ligand binds to this GPCR-αq, 
GDP bound on the alpha subunit is dissociated with GTP, resulting in the dissociation and 
activation of the alpha, beta and gamma subunits (Figure 1.6) (Kamato et al., 2017). The alpha 
subunit then activates phospholipase-C (PLC) on the plasma membrane of the cell (Figure 1.6) 
(Kamato et al., 2017). PLC cleaves Inositol Phospholipids (PIP2) into DAG and inositol 1,4,5-
triphosphate (IP3) (Figure 1.6) (Kamato et al., 2017). IP3 then activates IP3-gated Ca2+ 
channels on the SR, resulting in Ca2+ release (Figure 1.6) (Kania et al., 2017). Under basal 
conditions, the pseudosubstrate sequence binds the C4 region keeping the enzyme inactive 
(Kirwan et al., 2003). In cPKC’s, Ca2+ binds to Ca2+ binding residues within the C2 region of 
the regulatory domain allowing for the translocation of the kinase to the cell membrane (Eshete 
et al., 1998). However, in nPKC’s, the C2 region lacks Ca2+ binding residues and therefore is 
translocated to the membrane in a Ca2+ independent manner (Zhang & Aravind, 2010). At the 
cell membrane, DAG binds at the C1 region of the regulatory domain, resulting in the removal 
of the pseudosubstrate from the C4 region, thus activating the kinase (Kirwan et al., 2003). 
aPKC’s are activated by phosphatidylinositol’s such as phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) along with protein-protein interaction between pyruvate dehydrogenase 




Figure 1.6 Activation of PKC through GPCR. 
Binding of a ligand results in a downstream pathway resulting in activation of PLC which 
cleaves PIP2 into IP3 and DAG. IP3 then causes Ca2+ release from the SR. Ca2+ allows for the 
translocation of cPKC to the PM to interact with DAG for activation. DAG alone can activate 
nPKC. Created with Microsoft PowerPoint. 
 
1.4.3 PKC Activity in Diabetes  
The chronic hyperglycaemic environments seen in DM results in many molecular and 
biochemical changes which underlie the multitude of pathologies associated with DM. In 
normal physiological states, many proteins/lipids are glycosylated, with the covalent bonding 
of sugar molecules added to them with enzymatic control (Aebi, 2013). However, 
hyperglycemic environments can result in glycation, covalent bonding of sugar molecules to 
proteins and lipids without enzymatic function within hours (Adrover et al., 2008). These 
glycated proteins/lipids (Schiff bases) can then be turned into Amadori products if the 
hyperglycaemic environment persists, both of which are reversible using glycaemic control 
(Figure 1.7) (Pieters et al., 2007). Within weeks or months of chronic hyperglycaemic 
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environments, as seen in DM, Amadori products then become irreversible advanced glycated 
end products (AGE’s) (Figure 1.7) (Stitt et al., 1998). AGE’s can then result in 
pathophysiological changes resulting in inflammation, oxidative stress, and fibrosis which are 
linked to vascular dysfunction (Bodiga et al., 2014). Schiff bases, as well as Amadori products, 
can also lead to reactive intermediates (Figure 1.7) (Puttaiah et al., 2006). These reactive 
intermediates can then result in many physiological changes including increasing the synthesis 
of DAG (Xia et al., 1994). In the DM rat heart, PKC isoforms α, ε, β2 and δ have an increased 
activity, however, the consequence of each individual isoform is not well understood (Geraldes 
& King, 2010).  
 
 
Figure 1.7 Formation of AGE’s 
Glycation of proteins and lipids in the presence of glucose form Schiff bases. Within 
Weeks/Months, there is a build of reactive intermediates and AGEs seen in DM. It is the 





1.5 Aims and Hypothesis 
DM leads to many forms of molecular and biochemical changes which can result in post-
translational modification of proteins in the heart, including phosphorylation, oxidation, and 
glycation, which may explain the links between DM and CVD (Bodiga et al., 2014). As 
described in Section 1.4.3, hyperglycemic environments have been shown to cause an 
accumulation in DAG due to increased glycolytic intermediates, which then results in an 
increased activation of PKC, which has been associated with many vascular alterations 
including diabetic neuropathy (Geraldes & King, 2010). The molecular pathways through 
which DM has an increased risk or association to arrhythmia is not fully understood. It is well 
described that phosphorylation of RyR2 can result in SOICR, however, the effect of PKC 
phosphorylation on RyR2 and the occurrence of SOICR has not yet been investigated. Research 
investigating how an increase in PKC activation or expression, as seen in DM, can affect the 
RyR2 resulting in SOICR could serve as the molecular pathway linking DM and arrhythmia.  
 
Therefore, the aim of the study is to assess the effect of PKC on the occurrence of SOICR and 
the store dynamics of Ca2+ release. To test the aim, I will complete the following objectives: 
 
1. The effect of endogenous PKC on SOICR 
2. The effect of PKCα on SOICR and store dynamics 
3. The effect of PKCε on SOICR and store dynamics 
 
I hypothesise that activation and inhibition of endogenous PKC would result in an increase and 
decrease in the occurrence of SOICR respectively. I also hypothesise that both overexpression 
of PKCα and PKCε will increase the occurrence of SOICR due to a decrease in the release 




2.1 Cell Culture  
2.1.1 Preparation of HEK293 Cells for Subculture 
Flp-In T-REx human embryonic kidney 293 (HEK293) cells expressing RyR2 under the control 
of the tetracycline repressor were stored in at minus 80 °C. A 1 mL aliquot of thawed HEK293 
cells were added to a 75 cm2 culture flask containing 30 mL of pre-warmed (37°C) Dulbecco's 
Modified Eagle's Medium (DMEM) solution (1.8 mM CaCl2, 25 mM D-Glucose, 5.3 mM KCL, 
4 mM L-Glutamine, 0.8 mM MgSO4, 110 mM NaCl, 33 mM NaHCO2, 0.9 mM NaH2PO-H2O 
– pH 7.4) modified with 10% fetal bovine serum (FBS), 1% non-essential amino acids (NEAA), 
1% penicillin and 1% streptomycin. HEK293 cells were then cultivated in a humidified 
incubator, maintained at 37 °C with an atmosphere of 5% CO2. After 24 hours of cultivation, 
the existing growth medium was aspirated and replaced with 20 mL of fresh pre-warmed (37 
°C) DMEM solution.  
 
2.1.2 Subculture 
Once HEK293 cells in 75 cm2 or 25 cm2 culture flasks reached the desired confluence (~90%), 
they were then re-subcultured into either a 75 cm2 or 25 cm2 culture flask, where a maximum 
of nine passages was allowed before HEK293 cells were discarded and a new batch of HEK293 
cells were subcultured. First, the existing growth medium was aspirated and cells were washed 
twice with either 5 mL or 2 mL of pre-warmed sterile phosphate buffered saline (PBS) (2.7 mM 
KCL, 1.8 mM KH2PO4, 137 mM NaCl, 10 mM Na2HPO4 – pH 7.4), followed by a 5-minute 
incubation in either 3mL or 1mL PBS at room temperature (22 - 25 °C), depending on the 
culture flask size (75 cm2 or 25 cm2 respectively). The cell culture flask was then agitated to 
allow for detachment of the HEK293 cells from the internal surface. 17 mL or 6.5 mL of fresh 
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pre-warmed DMEM solution was added, respective to the culture flask size; 75 cm2 or 25 cm2, 
to attain a final volume of 7.5 mL or 20 mL. The mixture was then pipetted 3 times to ensure 
homogenous cell suspension. HEK293 cells from the 25 cm2 culture flask were then seeded 
onto glass coverslips for single-cell imaging or into another culture flask for later use. HEK293 
cells that were transferred into new 25 cm2 culture flask were diluted with fresh pre-warmed 
DMEM, with the volume determined by the required time of incubation. HEK293 cells from 
the 75 cm2 culture flask could then be transferred into 100 mm diameter cell culture dishes in 
preparation for cell lysate collection or subcultured into another culture flask for later use. Cell 
proliferation of HEK293 cells was maintained for 24-72 hours before cells were used for single-
cell imaging or the preparation of cell lysate collection for western blot analysis. An inverted 
microscope was used to assess cell confluence, and confirm the absence of bacterial or fungal 
contaminants.  
 
2.1.3 Preparation of HEK293 Cells for Imaging  
In preparation for single-cell imaging (Section 2.2), 13 mm diameter glass coverslips were 
sterilized in 70% ethanol and placed into a six-well culture plate (three glass coverslips per 
well). The coverslips were coated with poly-L-lysine for 5 minutes to facilitate cell adhesion. 1 
mL of suspended HEK293 cells from the 25 cm2 culture flask (Section 2.1.2) was then diluted 
in 18 mL of fresh pre-warmed (37 °C) DMEM, followed by an aliquot of 3 mL per well. In 
preparation of cell lysate collection for western blot analysis (Section 2.3), 1 mL of suspended 
HEK293 cells from the 75 cm2 culture flask (2.1.2) was added to each 100 mm diameter cell 





2.1.4 HEK293 cDNA Transfection 
HEK293 cells were transfected using the Ca2+-phosphate precipitation method which facilitates 
the endocytosis of cDNA into the cells (Graham & van der Eb, 1973). A 500 µL CaCl2-cDNA 
(62 µL CaCl2 + 5 µg cDNA + ddH2O to make 500 µL) transfection mixture was pipetted in a 
dropwise motion into a separate 50 mL tube containing 500 µL HEPES buffered saline (1.2 
mM CaCl2, 20 mM HEPES, 2.4 mM K2HPO4, 1.2 mM MgCl2, 115 mM NaCl – pH 7.4) where 
agitation of the solution was required to ensure co-precipitation. Thereafter, co-precipitate 
containing 0.9 µg of cDNA was then added into the individual wells of the culture plates 24 
hours post-seeding of the HEK293 cells (Section 2.1.3). For cytosolic Ca2+ imaging (Section 
2.2.1), individual wells were either transfected with or without PKCα/ε cDNA. Specifically, for 
luminal Ca2+ imaging (Section 2.2.2), 5 µg of D1ER cDNA was also included in the transfection 
mixture for each condition. For lysate collection (2.3.1), 5µg PKCα cDNA or mock (cDNA 
excluded) was added to each cell culture plates, 24 hours post-preparation of HEK293 cells 
(Section 2.1.3). 
 
2.1.5 Induction of RyR2 Expression  
Twenty-four hours post-transfection (Section 2.1.4) of HEK293 cells grown on 13 mm diameter 
glass coverslips for single-cell imaging, the existing growth medium was aspirated and each 
well was washed twice with 3 mL of pre-warmed DMEM. For cytosolic Ca2+ imaging (Section 
2.2.1), HEK293 cells were induced with 0.1 µg of tetracycline to induce RyR2 expression per 
well. For luminal Ca2+ imaging (Section 2.2.2), HEK293 cells were induced with 0.3 µg of 
tetracycline per well. HEK293 cells grown in 100 mm diameter culture plates for the collection 




2.2 Single-cell Imaging 
2.2.1 Cytosolic Ca2+ Imaging  
To assess SOICR, HEK293 cells grown on glass coverslips, transfected with or without PKCα/ε 
were imaged 16-20 hours post-induction (Section 2.1.5). The acetoxymethyl ester (AM) form 
of the Ca2+ indicator, Fluo-4 AM dissolved in dimethyl sulphoxide (DMSO) and 12% pluronic 
acid enabled the visualisation of Ca2+ release events, known as SOICR. Glass coverslips were 
rinsed in 0 mM Ca2+ Krebs-ringer HEPES (KRH) (25 mM HEPES, 125 mM NaCl, 6 mM 
Glucose, 5 mM KCL, 1.2 mM MgCl2 – pH 7.4) followed by an incubation in 1 mL of Ca
2+ free 
KRH containing 1 mg/mL of bovine serum albumin (BSA) with 2.5 µM Fluo-4 AM solution 
for 10 minutes, followed by a 10-minute wash in 0 mM Ca2+ KRH, before being mounted on 
the perfusion chamber.  Coverslips were imaged on an inverted microscope with a 20x objective 
lens while being superfused with KRH containing incremental Ca2+ concentrations (0, 0.1, 0.2, 
0.3, 0.5, 1 mM), followed by 1 mM Ca2+ + 20 mM caffeine (RyR2 agonist) for the duration of 
2, 4, 4, 4, 4, 4 and 2 minutes respectively (Kong et al., 2008). Caffeine was used to confirm 
RyR2 expression in each cell. The flow of the solutions was driven by gravity with a constant 
superfusion flow rate of ~3 mL per minute. The initial raw data collected was a video recording 
of HEK293 cells, within a chosen field of view, over the 24 minute experimental time course 
using NIS-Elements AR software (v4.0). The region of interest on the coverslip was determined 
using light microscopy to find an area of well distributed and appropriately confluent cells. The 
Fluo4-AM loaded in HEK293 cells underwent excitation at 470 nm with emission captured 
through a long-pass emission filter (>515 nm) with an exposure time of 100 milliseconds, while 
images were collected every 2 seconds. A separate region of interest (ROI) was drawn around 
150-250 cells per glass coverslip and the SOICR events were seen as transient increases 




2.2.1.1 Data Analysis 
The susceptibility to SOICR was determined by the Ca2+ concentration required to elicit the 
initial occurrence of fluorescent peaks. Traces of cytosolic Ca2+ fluorescence are presented as 
F/F0, with F indicative of the fluorescent intensity at time point, t, and F0 indicative of the 
fluorescent intensity recorded at 0 mM Ca2+. The cumulative fraction of cells experiencing 
SOICR at each Ca2+ concentration was then calculated and fitted with a non-linear regression 
for the individual glass coverslip, where the sample size (n) is the number of coverslips per 
condition. Cells that experienced SOICR events at 0 mM Ca2+ were excluded as they represent 
unhealthy cells. Cells that had no caffeine-induced Ca2+ transients at 1 mM Ca2+ with 20 mM 
caffeine were also excluded, as changes in fluorescent intensity could not be attributed to RyR2 
mediated release.  
 
2.2.2 Luminal Ca2+ Imaging 
To assess the characteristics of SOICR, HEK293 cells grown on glass coverslips that were 
transfected with D1ER, with or without co-transfection of PKCα/ε were imaged 16-20 hours 
post-induction. Glass coverslips were washed in 0 mM Ca2+ KRH for 10 minutes before being 
mounted on the perfusion chamber. Coverslips were imaged on an inverted microscope with a 
20 x objective lens while being superfused with KRH containing 0 mM Ca2+, 1 mM Ca2+, 2 
mM Ca2+, 2 mM Ca2+ + 2 mM tetracaine and 2 mM Ca2+ + 20 mM caffeine for the duration of 
2, 4, 7, 5 and 5 minutes respectively. 1-2 mM Ca2+ results in oscillations of fluorescence, where 
the downward peak represents Ca2+ release through RyR2 from the SR, while the upward peak 
is Ca2+ filling into the SR via SERCA. As the amount of Ca2+ load within the SR is dependent 
on the balance of SERCA-mediated influx and RyR2-mediated efflux, inactivation of RyR2 
renders the amount of Ca2+ load dependant on SERCA. Therefore, tetracaine, a RyR2 
antagonist, results in an upward peak of fluorescence due to Ca2+ filling the SR to the maximum 
(Overend et al., 1997). Caffeine, a RyR2 agonist, results in a downward peak of fluorescence 
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is due to complete depletion of Ca2+ through RyR2 from the SR (Kong et al., 2008). The flow 
of the solutions was driven by gravity with a constant superfusion flow rate of ~3 mL per 
minute. As described in Section 2.2.1.1, data of cells fluorescing over the 24 minute 
experimental time course were collected by NIS-Elements AR software (v4.0). D1ER 
underwent excitation at 436 nm with emissions of the yellow fluorescent protein (YFP) and 
cyan fluorescent protein (CFP) captured through a dual dichronic beamsplitter at 535 nm and 
480 nm respectively with an exposure time of 100 milliseconds. The two image recordings of 
the YFP and CFP channel were collected simultaneously every 2 seconds, where the amount of 
fluorescence resonance energy transfer (F) was determined by the ratio of these emissions 
(YFP/CFP). A ROI was drawn around 10-40 cells per glass coverslip. 
 
2.2.2.1 Data Analysis  
Four parameters were derived from the traces of luminal Ca2+ fluorescence for each cell, as 
shown in Figure 2.1; Fmax, Fmin, FSOICR, and Ftermi. Between 0-2 mM Ca
2+, oscillations of F 
represent the release of Ca2+ through the RyR2 from the SR (downward deflection) and the 
refilling of Ca2+ into the SR through SERCA activity (upward deflection). The average peaks 
of oscillation represent the luminal Ca2+ required to activate RyR2 Ca2+ release, termed the 
release threshold of SOICR (FSOICR), where the average nadir of oscillation represents the 
luminal Ca2+ required to inactivate RyR2 Ca2+ release and is termed the termination threshold 
(Ftermi) of SOICR. As described in Section 2.2.2, the subsequent addition of tetracaine and 
caffeine determined the maximum (Fmax) and minimum (Fmin) capacity of SR Ca
2+ store, 
respectively. These parameters were normalised to Fmin, and the characteristics of SOICR were 
calculated; store size (Fmax – Fmin), release threshold ([FSOICR – Fmin] / [Fmax – Fmin] x 100), 
termination threshold ([Ftermi – Fmin] / [Fmax – Fmin] x 100). The percentage of store size, release 
threshold and termination threshold of cells were then calculated and plotted, where the sample 




Figure 2.1 Luminal Ca2+ Fluorescent Trace. 
The parameters used to determine the characteristics of SOICR; maximum (Fmax), minimum 
(Fmin), release threshold (FSOICR) and termination threshold (Ftermi). Bar represents the 
concentration of the superfusate, and the length of the bar is proportional to the duration of 
superfusion. 
 
2.3 Western Blot 
2.3.1 Collection of HEK293 Cell Lysates  
HEK293 cells were grown in ten 100 mm diameter culture dishes for each condition (Section 
2.1.2). After 24 hours, the culture plates were either transfected with or without PKCa cDNA 
(Section 2.1.4). 24 hours post-transfection, the plates were then induced undiluted tetracycline 
(Section 2.1.5), 18 hours prior to harvesting of HEK293 cells. Growth medium was discarded 
and culture dishes were washed twice in PBS containing 0.5 mM ethylenediaminetetraacetic 
acid (EDTA) then incubated with 2.5 mL of PBS-EDTA for 10 minutes. Plates were agitated 
to allow the detachment of HEK293 cells from the internal surface. PBS-EDTA solution 
containing HEK293 cells was collected into a 50 mL tube, where a further 1.25 mL of PBS-
EDTA solution was added to each plate for the collection of any residual cells, making a total 
of 37.5 mL per condition. Tubes containing cells were centrifuged at 1000 g for 10 minutes. 
The supernatant was discarded and the pellet was resuspended with 2 mL of lysis buffer (1% 
CHAPS, 25 mM HEPES/Tris, 137 mM NaCl, 0.5% Soybean phosphatidylcholine – pH 7.05) 
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containing protease inhibitors (2 µg/ml Aprotinin, 1 Mm Benzamide, 2.5 mM DTT, 2 µg/ml 
Leupeptin, 2 µg/ml Pepstatin A, 0.525 mM PMSF) to minimise protein degradation for 1 hour 
on ice. To remove insoluble material, lysates were separated into two 1 mL eppendorff tubes 
and centrifuged at 16,000 g for 30 minutes at 4 °C, where the supernatant was then transferred 
into two CyroTubes and cryopreserved at minus 80 °C until required for sodium dodecyl sulfate 
(SDS) polyacrylamide gel electrophoresis (SDS-PAGE) (Section 2.3.4). The protein 
concentration was measured on a BioTek Take3 Micro-Volume Plate Reader, where for each 
condition, 3 biological samples were conducted.  
 
2.3.2 Preparation of Polyacrylamide Gels  
Two glass plates pre-cleaned with 70% ethanol were loaded onto a plastic clamp to form a gel 
cast. Running gel solution was pipetted to fill approximately 70% of the gel cast, this was 
overlaid with 1 mL of H2O to prevent gel desiccation. Running gel was left to set at room 
temperature for 1-hour. A 6% and 12% acrylamide running gel was made for total RyR2 and 
total PKCα with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) respectively. Once the 
gel had set, the H2O was removed and stacking gel solution was pipetted to fill the rest of the 
gel cast. While ensuring for no air bubbles, a 10 well plastic gel comb, with 1.5 mm wells, was 
introduced for the formation of wells and the gel was left to set at room temperature for 1 hour 










MilliQ-H2O 4632 3432 
Tris/ HCl (1.5 M - pH 8.8) 2000 2000 
Acrylamide (40%) 1200 2400 
SDS (10%) 80 80 
APS (Ammonium persulfate) (10%) 80 80 








Tris/ HCl (0.5 M - pH 6.8) 2000 
Acrylamide (40%) 800 
SDS (10%) 80 







2.3.3 Sample Preparation for SDS-PAGE  
Cell lysates were thawed and diluted with an appropriate volume of Laemmli’s sample buffer 
(SB) (10% β-mercaptoethanol, 0.004% Bromphenol Blue, 20% Glycerol, 4% SDS, 125 µM 
Tris-HCl). Samples were solubilised in a heating block at 95 °C for 7 minutes to denature the 
proteins and centrifuged at 1400 g for 2 minutes to remove insoluble material.   
 
2.3.4 SDS-PAGE 
SDS-PAGE was used to separate protein based on its molecular weight. The gel cassette 
containing the gel (Section 2.3.2) was introduced into the electrophoresis tank filled with 
running buffer (192 mM Glycine, 0.1% SDS, 25 mM Tris). The plastic comb was removed 
carefully from the gel where prepared samples containing 3µg/µL of protein (Section 2.3.3) 
were loaded from left to right after the addition of 7 µL of Precision Plus Protein Ladder in the 
first well to visualise protein migration; sample order was: Ladder, Mock #1, PKCα #1, Mock 
#2, PKCα #2, Mock #3 and PKCα #3. SDS-PAGE ran for 1-hour at 60 V, 400 mA to allow the 
samples to move through the stacking gel. The voltage was then turned up to 100V and left for 
4 or 1 hours for the 6% and 12% gel respectively.  
 
2.3.5 Membrane Transfer 
A wet-transfer method was used to transfer proteins to a nitrocellulose membrane. The gel was 
detached carefully from the cassette, removing the stacking gel layer before being placed within 
a transfer sandwich (sponge, filter paper, nitrocellulose membrane, gel, filter paper, sponge) 
held together by a transfer cassette. The transfer cassette was then introduced into a transfer 
tank filled with transfer buffer (192 mM Glycine, 20% Methanol, 0.01% SDS, 25 mM Tris). 
The protein samples were transferred from the gel to the nitrocellulose membrane overnight 
(900 minutes) in a 4 °C room, set at 54 V, 400 mA.  
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2.3.6 Membrane Blotting 
The membrane was removed from the transfer sandwich and placed in a container with Ponceau 
S total protein stain to check for clear band transfer to the membrane. The membrane was then 
washed in PBS, followed by two PBS with 0.5% tween-20 (PBS-T) washes. The membrane 
containing PKCα and GAPDH protein from the 12% gel was then cut into two separate 
membranes at the 50 kDa ladder band to allow the processing of the proteins independently. 
The membranes were then incubated in a 5% milk PBS-T solution for 1.5 hours to prevent non-
specific antibody binding, where all incubations occurred on a platform mixer unless stated 
otherwise. The membranes were then washed with PBS three times, ensuring complete removal 
of the milk PBS-T solution before being incubated with a primary antibody. The membrane 
containing RyR2 from the 6% gel was incubated in mouse-anti-RyR2 (Abcam, 1: 1,000 
dilution) for 4 hours. The membrane containing PKCα from the 12% gel was incubated in 
mouse-anti-PKCα (Abcam, 1: 1,000 dilution) for 2 hours. The membrane containing GAPDH 
was incubated in rabbit-anti-GAPDH conjugated with horseradish peroxidase (HRP) (Abcam, 
1: 2,500 dilution) for 2 hours. The membranes were then washed with PBS-T three times (5 
minutes, 10 minutes, 5 minutes) followed by three PBS washes. Membranes containing RyR2 
as well as PKCα were then incubated separately with the same HRP conjugated secondary 
antibodies, goat-anti-mouse (Abcam, 1: 20,000 dilution) for 2 hours, then washed with PBS-T 
three times (5 minutes, 10 minutes, 5 minutes) followed by three PBS washes. 
 
2.3.7 Membrane Developing 
Membranes were incubated in 4 mL of Super Signal West Pico Chemiluminescent Substrate 
for 5 minutes while tilting the box. The membrane was then placed between two clear plastic 




2.3.8 Western blot analysis  
Densitometry analysis was performed with GeneTools (v4.0) software, normalised to GAPDH 
([Density of RyR2 or PKCα] / [Density of GAPDH from the same sample]). The data was then 
processed to give the fold change of PKCα transfected HEK293 cells to mock transfected 
HEK293 cells for both total RyR2 and PKCα ([normalised PKCα or Mock transfection density] 
/ [Mock transfection density average]).  
 
2.4 Statistical Analysis  
All statistical analyses were performed on GraphPad Prism (v6.0) software, where statistical 
significance is denoted as p ≤ 0.05 *, p ≤ 0.01 **, p ≤ 0.001 ***, data are expressed as mean ± 
standard error of the mean (SEM). For data sets that presented a normal distribution; western 
blot analysis and luminal Ca2+ imaging analysis, an unpaired two-tailed student’s t-test was 
used. For data sets that contained more than two conditions including; luminal Ca2+ imaging, a 
one-way analysis of variance (ANOVA) was performed. For data sets that contained two 
variables with more than two conditions including; cytosolic Ca2+ imaging analysis, a two-way 
ANOVA was performed along with the most appropriate post-hoc test, mentioned for each 




.   
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3 Results  
3.1 Cell Viability  
Before using the HEK293 cells they were first examined under a microscope to check cell 
health and density. Light microscopy was used to confirm the confluence of the HEK293 cells 
and to examine for bacterial or fungal contamination. An inverted microscope was used to 
confirm the uptake of the cytosolic Ca2+ indicator dye, Fluo-4 AM into the HEK293 cells prior 
to cytosolic Ca2+ imaging and to confirm the transfection of the luminal Ca2+ indicator protein, 
D1ER prior to luminal Ca2+ imaging. Figure 3.1 A shows a non-contaminated and well-
distributed view of HEK293 cells. Figure 3.1 B shows uptake of Fluo-4 AM while Figure 3.1 
C shows transfection of D1ER protein. For D1ER note the reticular pattern indicating 







Figure 3.1 HEK293 Cells Visualised Using Microscopy. 
(A) Non-contaminated, well distributed HEK293 cells. (B) Successful loading of Fluo-4 AM 
into HEK293 cells. (C) Successful D1ER transfection in HEK293 cells. Scale bar 50µm. 
 
3.2 Endogenous PKC 
3.2.1 Cytosolic Ca2+ Imaging 
3.2.1.1 Endogenous PKC Activation  
In DM, there is an increase in the accumulation and synthesis of DAG resulting in increased 
PKC activity. To mimic this effect in HEK293 cells, the PKC activator 1,2-dioctanoyl-sn-
glycerol (Dic8), a DAG analogue, was used to activate endogenous PKC (Stahelin et al., 2005). 
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See Figure 3.4 for endogenous PKC expression level quantification. HEK293 cells were loaded 
with the cytosolic Ca2+ indicator dye, Fluo-4 AM and continuously superfused with KRH 
containing increasing Ca2+ concentrations (0, 0.1, 0.2, 0.3, 0.5, 1 mM) to elicit SOICR. To 
confirm RyR2 expression the HEK293 cells were superfused with 1 mM Ca2+ KRH solution 
containing 20 mM caffeine at the end of each experiment. Caffeine is a RyR2 agonist and 
depletes the luminal Ca2+ store which can be observed as a large increase in cytosolic Ca2+. 
SOICR events were visualised as transient peaks in the cytosolic Ca2+ fluorescence as seen in 
Figure 3.2 A. The cumulative fraction of cells in each condition (Vehicle treated, 10 µM Dic8 
treated and 20 µM Dic8 treated HEK293 cells) exhibiting Ca2+ oscillations (SOICR events) was 
plotted against the concentration of Ca2+. These data points were fitted with a non-linear 
regression (Vehicle treated HEK293 cells R2 = 0.87, 10 µM Dic8 treated HEK293 cells R2 = 
0.90 and 20 µM Dic8 treated HEK293 cells R2 = 0.84) and statistical significance assessed with 
a two-way ANOVA with a Dunnett’s post hoc test. As shown in Figure 3.2 B, an increase in 
Ca2+ concentration in the superfusate resulted in an increase in the fraction of cells undergoing 
SOICR in a dose-response manner for each condition as expected. The addition of 10µM Dic8 
resulted in an increase in the percentage of cells undergoing SOICR compared to the vehicle 
treated HEK293 cells at 0.3 mM Ca2+ (47.69 ± 3.7 versus 34.85 ± 4.0) (p = 0.013). Application 
of 20 µM Dic8 led to a greater increase in the percentage of cells undergoing SOICR compared 
to the vehicle treated HEK293 cells at 0.2 (30.07 ± 13.11 versus 16.82 ± 3.38) (p = 0.046), 0.3 
(52.37 ± 9.27 versus 34.85 ± 4.0) (p = 0.006), 0.5 (67.23 ± 4.79 versus 51.32 ± 2.93) (p = 0.014) 







Figure 3.2 Dic8 Increases the Occurrence of SOICR.  
HEK293 cells loaded with the cytosolic Ca2+ indicator, Fluo-4 AM were superfused with 
increasing Ca2+ concentrations [0, 0.1, 0.2, 0.3, 0.5, 1mM]. (A) Representative Fluo-4 AM trace 
of cytosolic Ca2+ fluorescence, expressed as F/F0. Bar represents superfusate with length of bar 
proportional to duration of superfusion. (B) Cumulative fraction of cells exhibiting SOICR at 
each Ca2+ concentration. Vehicle treated HEK293 cells (red line) n = 11, 10µM Dic8 treated 
HEK293 cells (blue line) n = 8 and 20µM Dic8 treated HEK293 cells (green line) n = 4. n 
represents number of coverslips per condition, with 150-250 cells counted per coverslip. Data 





3.2.1.2 Endogenous PKC Inhibition 
A multi-isoform PKC inhibitor, Go6983 was used to determine if inhibition of endogenous 
PKC influenced SOICR in HEK293 cells. Go6983 inhibits PKC by binding the ATP binding 
site of the catalytic domain (Sakwe et al., 2005). As described in Section 3.2.1.1, HEK293 cells 
were loaded with Fluo-4 AM and continuously superfused with KRH containing increasing 
Ca2+ concentrations to elicit SOICR in these cells. SOICR was visualised as transient peaks in 
the cytosolic Ca2+ fluorescence as seen in Figure 3.3 A. The cumulative fraction of cells for 
each condition (Vehicle treated and 5µM Go6983 treated HEK293 cells) exhibiting Ca2+ 
oscillations was plotted against the concentration of Ca2+. These data points were fitted with a 
non-linear regression (Vehicle treated HEK293 cells R2 = 0.94 and 5µM Go6983 treated 
HEK293 cells R2 = 0.89) and statistical significance assessed with a two-way ANOVA with a 
Sidak’s post hoc test. As described in Section 3.2.1.1, an increase in Ca2+ concentration results 
in an increase of fraction of cells undergoing SOICR seen in Figure 3.3 A. Figure 3.3 B shows 
that inhibition of endogenous PKC in HEK293 cells using Go6983 results in an increase in the 
percentage of cells undergoing SOICR compared to the mock transfected HEK293 cells at 0.2 
(40.2 ± 4.82 versus 16.83 ± 3.07), 0.3 (57.42 ± 4.49 versus 33.03 ± 2.37), 0.5 (66.37 ± 3.25 
versus 45.61 ± 1.96) and 1 mM Ca2+ (75.11 ± 2.41 versus 53.86 ± 0.69) (p < 0.0001 for all 
points). Whilst performing this assay a member in the lab has shown that the use of ATP 
inhibitors directly affects the RyR2, resulting in an increase in the occurrence of SOICR, 
therefore, I discontinued using Go6983 for the rest of the study as any results obtained could 









Figure 3.3 Go6983 Increases the Occurrence of SOICR.  
HEK293 cells loaded with the cytosolic Ca2+ indicator, Fluo-4 AM were superfused with 
increasing Ca2+ concentrations [0, 0.1, 0.2, 0.3, 0.5, 1mM]. (A) Representative Fluo-4 AM trace 
of cytosolic Ca2+ fluorescence, expressed as F/F0. Bar represents superfusate with length of bar 
proportional to duration of superfusion. (B) Cumulative fraction of cells exhibiting SOICR at 
each Ca2+ concentration. Vehicle treated HEK293 cells (red line) n = 7 and 5uM Go6983 treated 
HEK293 cells (blue line) n = 8. n represents number of coverslips per condition, with 150-250 





3.3 PKCα Overexpression 
As activation of endogenous PKC led to an increase in SOICR, I next explored which isoform 
could be responsible. 
3.3.1 Western Blot Analysis 
Before determining the functional effect of increasing PKCα expression I first determined the 
endogenous PKCα expression level (the prevalent isoform in HEK293 cells) and increase 
obtained by transfecting with PKCα, cDNA using western blotting. Cell lysates harvested from 
HEK293 cells transfected with or without PKCα cDNA were loaded into a 6% (RyR2) and 12% 
polyacrylamide gels (PKC and GAPDH) to allow protein separation based on their molecular 
weight using SDS-PAGE. Following wet-transfer of the proteins onto a nitrocellulose 
membrane, primary and secondary antibodies followed by enhanced chemiluminescence was 
used to visualise the proteins of interest; RyR2, PKCα, and GAPDH. A protein ladder was used 
to confirm the molecular weight of the protein of interest. The expression of each protein of 
interest (RyR2 and PKC) was normalised with GAPDH and modified to represent fold changes. 
Statistical significance was assessed with an unpaired t-test. The RyR2 protein band appeared 
above the 250 kDa protein ladder band as RyR2 has an expected weight of 563 kDa. The PKCα 
and GAPDH protein bands appeared to be adjacent to the protein ladder bands of 75 kDa and 
37 kDa aligning with their respective expected weight of 75 kDa and 37 kDa. Figure 3.4 C 
shows representative images of the total RyR2, PKCα and GAPDH bands at each condition. As 
seen in Figure 3.4 B, PKCα transfected HEK293 cells resulted in an approximately 5.5-fold 
increase in total PKCα compared to that of mock transfected HEK293 cells (5.45 ± 0.41 versus 
1 ± 0.11) (p = 0.0005). PKCα transfected HEK293 cells resulted in no change in total RyR2 












Figure 3.4 PKCα Transfection Results in Robust Expression.  
Western blot analysis of harvested HEK293 cell lysates with or without PKCα were developed 
and analysed. (A) Images of RyR2, PKCα and GAPDH total protein bands for PKCα and mock 
transfected HEK293 cell lysates. (B) PKCα total normalised against GAPDH and adjusted to 
show fold changes of protein for PKCα transfected HEK293 cells (blue bar) against the mock 
transfected HEK293 cells (red bar) n = 3 independent lysates per condition. (C) RyR2 total 
normalised against GAPDH and adjusted to show fold changes of protein for PKCα transfected 
HEK293 cells (blue bar) against the mock transfected HEK293 cells (red bar) n = 3 independent 







3.3.2 Cytosolic Ca2+ Imaging  
3.3.2.1 PKCα Overexpression 
Not only is PKCα the most expressed PKC isoform in the heart, but PKCα has been shown to 
have an increase expression/activity in DM. As seen in Figure 3.2 B, activation of endogenous 
PKC increased the incidence of SOICR; however, the isoform(s) responsible are unknown.  
As PKCα is the isoform with the highest expression in the heart, HEK293 cells were transfected 
with or without PKCα and its effect on SOICR was assessed. As described in Section 3.2.1.1, 
HEK293 cells were loaded with Fluo-4 AM and continuously superfused with KRH containing 
increasing Ca2+ concentrations to elicit SOICR. SOICR was visualised as transient peaks in the 
cytosolic Ca2+ fluorescence (Figure 3.5 A). The cumulative fraction of cells for each condition 
(Mock transfected and PKCα transfected HEK293 cells) exhibiting Ca2+ oscillations was 
plotted against the concentration of Ca2+. These data points were fitted with a non-linear 
regression (Mock transfected HEK293 cells R2 = 0.83 and PKCα transfected HEK293 cells R2 
= 0.84) and statistical significance assessed with a two-way ANOVA with a Sidak’s post hoc 
test. As mentioned in Section 3.2.1.1, an increase in Ca2+ concentration results in an increase 
of fraction of cells undergoing SOICR seen in Figure 3.5 A. PKCα transfected HEK293 cells 
had an increase in the percentage of cells undergoing SOICR compared to the mock transfected 
HEK293 cells at 0.3 mM Ca2+ (34.04 ± 2.69 versus 24.91 ± 3.84) (p = 0.047). PKCα transfected 
HEK293 cells appeared to have no changes in the percentage of cells undergoing SOICR at 0.1, 








Figure 3.5 PKCα has a Small Effect on the Occurrence of SOICR.  
HEK293 cells loaded with the cytosolic Ca2+ indicator, Fluo-4 AM were superfused with 
increasing Ca2+ concentrations [0, 0.1, 0.2, 0.3, 0.5, 1mM]. (A) Representative Fluo-4 AM trace 
of cytosolic Ca2+ fluorescence, expressed as F/F0. Bar represents superfusate with length of bar 
proportional to duration of superfusion. (B) Cumulative fraction of cells exhibiting SOICR at 
each Ca2+ concentration. Mock transfected HEK293 cells (red line) n = 13 and PKC transfected 
HEK293 cells (blue line) n = 25. n represents number of coverslips per condition, with 150-250 





3.3.2.2 PKCα Overexpression and Activation with Dic8 
Figure 3.5 B shows overexpression of PKCα results in a small change in the incidence of 
SOICR. Based on Figure 3.2 B, showing that activation of endogenous PKC with Dic8 
increased the incidence of SOICR I decided to see if PKCα overexpression with or without 
Dic8 could further increase the incidence of SOICR. As described in Section 3.2.1.1, HEK293 
cells were loaded with Fluo-4 AM and continuously superfused with KRH containing 
increasing Ca2+ concentrations to elicit SOICR in these cells. SOICR was visualised as transient 
peaks in the cytosolic Ca2+ fluorescence as seen in Figure 3.6 A. The cumulative fraction of 
cells for each condition (Vehicle treated and 10µM Dic8 treated PKCα transfected HEK293 
cells) exhibiting Ca2+ oscillations was plotted against the concentration of Ca2+. These data 
points were fitted with a non-linear regression (Vehicle treated PKCα transfected HEK293 cells 
R2 = 0.82 and 10µM Dic8 treated PKCα transfected HEK293 cells R2 = 0.84) and statistical 
significance assessed with a two-way ANOVA with a Sidak’s post hoc test. Consistent with 
Section 3.2.1.1, an increase in Ca2+ concentration resulted in an increase of fraction of cells 
undergoing SOICR seen in Figure 3.6 A. I initially believed that PKCα overexpression may 
have only shown a small effect on SOICR, seen in Figure 3.5 due to a lack of agonists, however, 
in Figure 3.6 B, there was no change in the percentage of cells undergoing SOICR between the 
PKCα transfected HEK293 cells treated with or without the PKC agonist, Dic8, at all Ca2+ 
concentrations (p > 0.05) suggesting that PKCα may not be responsible for the increase in 










Figure 3.6 Dic8 does not Further Increase the Effect of PKCα Overexpression.  
HEK293 cells loaded with the cytosolic Ca2+ indicator, Fluo-4 AM were superfused with 
increasing Ca2+ concentrations [0, 0.1, 0.2, 0.3, 0.5, 1mM]. (A) Representative Fluo-4 AM trace 
of cytosolic Ca2+ fluorescence, expressed as F/F0. Bar represents superfusate with length of bar 
proportional to duration of superfusion. (B) Cumulative fraction of cells exhibiting SOICR at 
each Ca2+ concentration. Vehicle treated PKCα transfected HEK293 cells (red line) n = 4 and 
Dic8 treated PKCα transfected HEK293 cells (blue line) n = 4. n represents number of 
coverslips per condition, with 150-250 cells counted per coverslip. Data expressed as mean ± 




3.3.3 Luminal Ca2+ Imaging 
3.3.3.1 PKCα Overexpression  
To confirm the small effect of PKCα on the occurrence of SOICR in Figure 3.5, SR store 
dynamics were assessed. HEK293 cells were transfected with the luminal Ca2+ indicator 
protein, D1ER and continuously superfused with KRH containing increasing Ca2+ 
concentrations (0, 1, 2 mM) to elicit SOICR in these cells. To fill the Ca2+ store to maximum, 
HEK293 cells were superfused with a 2 mM Ca2+ KRH solution containing 2 mM tetracaine 
which blocks RyR2. Finally, to deplete the Ca2+ store, HEK293 cells were superfused with 2 
mM Ca2+ KRH solution containing 20 mM caffeine. Fmax, Fmin, FSOICR and Ftermi parameters 
were determined from the single cell luminal Ca2+ fluorescence traces and normalised to Fmin 
to calculate SOICR characteristics, seen in Figure 3.7 A. The percentage of store size (Fmax – 
Fmin), release threshold ([FSOICR – Fmin] / [Fmax – Fmin] x 100) and termination threshold ([Ftermi 
– Fmin] / [Fmax – Fmin] x 100) were calculated for each condition (Mock transfected HEK293 
cells and PKCα transfected HEK293 cells) and statistical significance was assessed with an 
unpaired two-tailed student’s t-test. Figure 3.7 B and Figure 3.7 C shows PKCα results in no 
change in the total store size and release threshold between mock and PKCα transfected 
HEK293 cells (p > 0.05), inconsistent with the small change in SOICR observed in Figure 3.5 
B. Figure 3.7 D shows that PKCα transfected HEK293 cells have an increased termination 

















Figure 3.7 PKCα Reduces Store Size.  
HEK293 cells transfected with the luminal Ca2+ indicator protein, D1ER were superfused with 
increasing Ca2+ concentrations [0,1, 2mM] followed by tetracaine and caffeine. (A) 
Representative D1ER trace luminal Ca2+ fluorescence, expressed as F/F0. Bar represents 
superfusate with length of bar proportional to duration of superfusion. Bar graph of the 
percentage of (B) store size, (C) release threshold and (D) termination threshold for each 
condition. Mock transfected HEK293 cells (red bar) n = 110 and PKCε transfected HEK293 
cells (blue bar) n = 30. n represents the number of cells per condition. Data expressed as mean 
± SEM.   
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3.3.3.2 PKCα Overexpression and Activation with Dic8 
To determine the effect of PKCα plus Dic8 on the occurrence of SOICR, seen in Figure 3.6, SR 
store dynamics were also assessed and compared against the results from Figure 3.7.  
HEK293 cells were co-transfected with PKCα and the luminal Ca2+ indicator protein, D1ER 
and continuously superfused with KRH containing increasing Ca2+ concentrations (0, 1, 2 mM) 
to elicit SOICR in these cells. To fill the Ca2+ store to maximum, HEK293 cells were superfused 
with a 2 mM Ca2+ KRH solution containing 2 mM tetracaine which blocks RyR2. Finally, to 
deplete the Ca2+ store, HEK293 cells were superfused with 2 mM Ca2+ KRH solution containing 
20 mM caffeine. Fmax, Fmin, FSOICR and Ftermi parameters were determined from the single cell 
luminal Ca2+ fluorescence traces and normalised to Fmin to calculate SOICR characteristics. The 
percentage of store size (Fmax – Fmin), release threshold ([FSOICR – Fmin] / [Fmax – Fmin] x 100) 
and termination threshold ([Ftermi – Fmin] / [Fmax – Fmin] x 100) were calculated for Dic8 treated 
PKCα transfected HEK293 cells, and statistical significance was assessed with a one-way 
ANOVA. Figure 3.8 A and C shows no change in the total store size and termination threshold 
between the mock, PKCα transfected, and PKCα transfection with Dic8 (p > 0.05). Figure 3.8 
B shows that PKCα transfection with Dic8 results in a significant decrease in the release 
threshold compared to the mock and PKCα transfected HEK293 cells (85.56 ± 1.51 versus 
90.77 ± 0.53 and 90.39 ± 0.74) (p = 0.001, 0.006). The reduction in the release threshold of 
SOICR could either be due to PKCα being further activated with Dic8 or an independent effect 
of Dic8. An independent effect of Dic8 on the release threshold for SOICR would be consistent 














Figure 3.8 Overexpression of PKCα with Dic8 Reduces Release Threshold. 
HEK293 cells transfected with the luminal Ca2+ indicator protein, D1ER were superfused with 
increasing Ca2+ concentrations [0,1, 2mM] followed by tetracaine and caffeine. Bar graph of 
the percentage of (A) store size, (B) release threshold and (C) termination threshold for each 
condition. Mock transfected HEK293 cells (red bar) n = 110, PKCε transfected HEK293 cells 
(blue bar) n = 30 and Dic8 treated PKCε transfected HEK293 cells (green bar) n = 27. n 
represents the number of cells per condition. Data expressed as mean ± SEM.  
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3.4 PKCε Overexpression 
3.4.1 Cytosolic Ca2+ Imaging  
3.4.1.1 PKCε Overexpression 
As endogenous activation of PKC in HEK293 cells using Dic8 resulted in an increase in the 
occurrence of SOICR (Figure 3.2 B) and PKCα isoform appears to have only a small effect on 
the occurrence of SOICR (Figure 3.5 B), the next logical step was to determine the effect of 
other PKC isoforms, specifically PKCε, which is also expressed in HEK293 cells. PKCε differs 
from PKCα based on the structure and its mode of activation, as it requires only DAG and not 
Ca2+. PKCε is also highly expressed in the heart and has also been shown to have an increased 
expression/activity in DM. As described in Section 3.2.1.1, HEK293 cells were loaded with 
Fluo-4 AM and continuously superfused with KRH containing increasing Ca2+ concentrations 
to elicit SOICR in these cells. SOICR was visualised as transient peaks in the cytosolic Ca2+ 
fluorescence as seen in Figure 3.9 A. The cumulative fraction of cells for each condition (Mock 
transfected and PKCε transfected HEK293 cells) exhibiting Ca2+ oscillations was plotted 
against the concentration of Ca2+. These data points were fitted with a non-linear regression 
(Mock transfected HEK293 cells R2 = 0.88 and PKCε transfected HEK293 cells R2 = 0.86) and 
statistical significance assessed with a two-way ANOVA with a Sidak’s post hoc test. As in 
Section 3.2.1.1, an increase in Ca2+ concentration results in an increase of fraction of cells 
undergoing SOICR seen in Figure 3.9 A. PKCε transfected HEK293 cells had an increase in 
the percentage of cells undergoing SOICR compared to the mock transfected HEK293 cells at 
0.5 (62.61 ± 5.1 versus 40.33 ± 3.06) (p = 0.0008) and 1 mM Ca2+ (70.8 ± 4.43 versus 45.6 ± 









Figure 3.9 PKCε Increases the Occurrence of SOICR.  
HEK293 cells loaded with the cytosolic Ca2+ indicator, Fluo-4 AM were superfused with 
increasing Ca2+ concentrations [0, 0.1, 0.2, 0.3, 0.5, 1mM]. (A) Representative Fluo-4 AM trace 
of cytosolic Ca2+ fluorescence, expressed as F/F0. Bar represents superfusate with length of bar 
proportional to duration of superfusion. (B) Cumulative fraction of cells exhibiting SOICR at 
each Ca2+ concentration. Mock transfected HEK293 cells (red line) n = 6 and PKCε transfected 
HEK293 cells (blue line) n = 6. n represents number of coverslips per condition, with 150-250 




3.4.1.2 PKCε Overexpression and Activation with Dic8 
Figure 3.9 B showed transfection of PKCε results in a significant increase in the incidence of 
SOICR in HEK293 cells. Based on Figure 3.2 B, showing that activation of endogenous PKC 
with Dic8 increased the incidence of SOICR I decided to see if PKCε overexpression with or 
without Dic8 could increase the incidence of SOICR even further. As described in Section 
3.2.1.1, HEK293 cells were loaded with Fluo-4 AM and continuously superfused with KRH 
containing increasing Ca2+ concentrations to elicit SOICR in these cells. SOICR was visualised 
as transient peaks in the cytosolic Ca2+ fluorescence as seen in Figure 3.10 A. The cumulative 
fraction of cells for each condition (Vehicle treated and 10µM Dic8 treated PKCε transfected 
HEK293 cells) exhibiting Ca2+ oscillations was plotted against the concentration of Ca2+. These 
data points were fitted with a non-linear regression (Vehicle treated PKCε transfected HEK293 
cells R2 = 0.95 and 10µM Dic8 treated PKCε transfected HEK293 cells R2 = 0.93) and statistical 
significance assessed with a two-way ANOVA with a Sidak’s post hoc test. As in Section 
3.2.1.1, an increase in Ca2+ concentration results in an increase of fraction of cells undergoing 
SOICR seen in Figure 3.10 A. In Figure 3.10 B, there was no change in the percentage of cells 
undergoing SOICR between the PKCε transfected HEK293 cells treated with or without Dic8 
at all Ca2+ concentrations (p > 0.05), suggesting the overexpressed PKCε activity cannot be 









Figure 3.10 Dic8 does not Further Increase the Effect on the Occurrence of SOICR in 
Cells Transfected with PKCε.  
HEK293 cells loaded with the cytosolic Ca2+ indicator, Fluo-4 AM were superfused with 
increasing Ca2+ concentrations [0, 0.1, 0.2, 0.3, 0.5, 1mM]. (A) Representative Fluo-4 AM trace 
of cytosolic Ca2+ fluorescence, expressed as F/F0. Bar represents superfusate with length of bar 
proportional to duration of superfusion. (B) Cumulative fraction of cells exhibiting SOICR at 
each Ca2+ concentration. Vehicle treated PKCε transfected HEK293 cells (red line) n = 4 and 
Dic8 treated PKCε transfected HEK293 cells (blue line) n = 4. n represents number of 






3.4.2 Luminal Ca2+ Imaging 
3.4.2.1 PKCε Overexpression  
To confirm the effect of PKCε on the occurrence of SOICR in Figure 3.9, SR store dynamics 
were also assessed. HEK293 cells were co-transfected with PKCε and the luminal Ca2+ 
indicator protein, D1ER. As described in Section 2.3.3.1, cells are continuously superfused with 
different KRH solutions; 0, 1, 2 mM Ca2+, 2 mM Ca2+ with 2 mM tetracaine and 2 mM Ca2+ 
with 20 mM caffeine. Fmax, Fmin, FSOICR and Ftermi parameters were determined from the single 
cell luminal Ca2+ fluorescence traces and normalised to Fmin to calculate SOICR characteristics, 
seen in Figure 3.11 A. The percentage of store size (Fmax – Fmin), release threshold ([FSOICR – 
Fmin] / [Fmax – Fmin] x 100) and termination threshold ([Ftermi – Fmin] / [Fmax – Fmin] x 100) were 
calculated for each condition (Mock transfected HEK293 cells and PKCε transfected HEK293 
cells) and statistical significance was assessed with an unpaired two-tailed student’s t-test. 
Figure 3.11 B shows no change in the total store size between the PKCε and mock transfected 
HEK293 cells (p = 0.85). Figure 3.11 C and Figure 3.11 D show that PKCε transfected HEK293 
cells resulted in a decrease in both termination threshold (38.22 ± 1.61 versus 43.4 ± 1.01) (p = 
0.005) and release threshold (87.47 ± 1.07 versus 90.77 ± 0.53) (p = 0.002) respectively, 












Figure 3.11 PKCε reduces release and termination threshold.  
HEK293 cells transfected with the luminal Ca2+ indicator protein, D1ER were superfused with 
increasing Ca2+ concentrations [0,1, 2mM] followed by tetracaine and caffeine. (A) 
Representative D1ER trace luminal Ca2+ fluorescence. Bar represents superfusate with length 
of bar proportional to duration of superfusion. Bar graph of the percentage of (B) store size, (C) 
release threshold and (D) termination threshold for each condition. Mock transfected HEK293 
cells (red bar) n = 110 and PKCε transfected HEK293 cells (blue bar) n = 52. n represents the 





In this study, I hypothesised that one of the possible molecular pathways in which DM patients 
have an increased risk and association with arrhythmia was due to excessive PKC activity, due 
to an accumulation of DAG, resulting in phosphorylation of RyR2 triggering SOICR a 
precursor for arrhythmogenesis. To test this hypothesis, I first looked at the effect of activation 
or inhibition of endogenous PKC in HEK293 cells on the occurrence of SOICR. My results 
showed that activation of PKC using Dic8 increased the occurrence of SOICR, suggesting that 
one or many of the PKC isoforms expressed endogenously in HEK293 can phosphorylate the 
RyR2, resulting in the increase in SOICR (Figure 3.2). I then showed that when inhibiting 
endogenous PKC in HEK293 cells, using Go6983, there is a massive increase in the occurrence 
of SOICR; this was unexpected as an increased activity of endogenous PKC also showed an 
increase in the occurrence of SOICR (Figure 3.3). The result of increased and decreased 
endogenous PKC activity in HEK293 suggests that that either Dic8 or Go6983 may have effects 
on proteins other than PKC or that modulation of PKC in HEK293 cells alters multiple 
pathways linked to SOICR. Through the work of others in the lab, we found that Go6983 is 
likely to be affecting RyR2 directly (See Section 4.1.2). Disregarding the effect of Go6983 my 
other data suggest that activation of PKC increases the incidence of SOICR as hypothesised.  
 
As it was unclear which PKC isoform/s resulted in an increase of SOICR occurrence using 
Dic8, I next aimed to determine the isoform responsible. I chose to start with examining the 
effect of PKCα on the occurrence of SOICR, as it has the highest isoform expression in the 
human heart (Simonis et al., 2007). To look at the effect of PKCα I overexpressed this isoform 
in my HEK293 cell model. Western blot analysis showed that PKCα was successfully 
transfected, where its expression increased by 5.5-fold when transfected with PKCα cDNA 
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(Figure 3.4). My research showed that overexpression of PKCα in HEK293 cells resulted in a 
small increase in the occurrence of SOICR at low Ca2+ concentrations, which suggests that 
PKCα is unlikely to be the isoform responsible for the effect of endogenous activation of PKC 
in HEK293 cells (Figure 3.5). As a cPKC isoform, PKCα requires both Ca2+ and DAG for 
activation, hence when I overexpressed PKCα in HEK293 cells, I was uncertain if there are 
enough substrates (DAG or Ca2+) for activation. As activation of endogenous PKC using Dic8 
increased SOICR occurrence, I looked at the effect of overexpressed PKCα, with or without 
Dic8. My results showed that PKCα plus Dic8 did not result in an increase in SOICR occurrence 
compared to PKCα alone, suggesting that PKCα may not be phosphorylating the RyR2, 
resulting in SOICR (Figure 3.6) under the conditions used in my assay. To further investigate 
whether PKCα affects SR dynamics, HEK293 cells were co-transfected with both D1ER and 
PKCα. My results show that overexpression of PKCα does not alter the SR store size or the 
release threshold for SOICR, but instead results in an increase in the termination threshold, 
suggesting overexpressed PKCα in HEK293 cells has no effect on increasing the occurrence of 
SOICR but may actually reduce the magnitude of release (Figure 3.7). To then investigate the 
whether PKCα with Dic8 affects SR dynamics, HEK293 cells were co-transfected with both 
D1ER and PKCα, then treated with or without Dic8. My results show that overexpression of 
PKCα with Dic8 show a decrease in the release threshold, suggesting overexpression of PKCα 
with Dic8 should result in an increase in the occurrence of SOICR (Figure 3.8). Interestingly to 
note is that the significant increase in the termination threshold by overexpressed PKCα in 
Figure 3.7 is lost when using a one-way ANOVA with three conditions.  
 
Following on from PKCα, I then decided to test a nPKC isoform that also has high expression 
in the heart, PKCε, to see if there is a difference between the cPKC and nPKC subclasses. The 
rationale for looking at a nPKC was that they do not need Ca2+ to be activated, just DAG which 
I could add exogenously if required. My research showed that overexpression of PKCε in 
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HEK293 cells resulted in a dramatic increase in the occurrence of SOICR (Figure 3.9). This 
suggests that PKCε may be one of the isoforms responsible for the increase in SOICR 
occurrence due to endogenous activation of PKC in HEK293 cells, as these cells express PKCε 
endogenously (Sakwe et al., 2004). As PKCε only requires DAG for activation, the addition of 
Dic8 in HEK293 cells with overexpressed PKCε may result in a greater level of activity. When 
I looked at the effect of overexpressed PKCε, with or without Dic8, my results showed that 
PKCε with Dic8 did not result in a further increase in SOICR occurrence, suggesting that the 
overexpressed PKCε was already fully activated by endogenous DAG (Figure 3.10). As 
HEK293 cell were grown in high glucose concentrations their DAG levels could already be 
very high (Ayo et al., 1991). To understand the mechanism behind the increased occurrence of 
SOICR seen in overexpression of PKCε, I looked at its effect on SR dynamics. HEK293 cells 
were co-transfected with D1ER and PKCε, and my results show that overexpression of PKCε 
does not alter the SR store size and instead results in a decrease in both the release and 
termination thresholds for SOICR (Figure 3.11). This suggests that PKCε phosphorylates the 
RyR2 decreasing the release threshold for SOICR making it more likely to be surpassed 
increasing the incidence of SOICR. This is consistent with the proposed effects of PKA and 
CaMKII phosphorylation of RyR2 (Xiao et al., 2007; McCauley & Wehrens, 2011).   
 
4.1.1 PKC Activation Effect on SOICR 
As hypothesised, Dic8 increased the occurrence of SOICR in endogenous HEK293 cells. As 
Dic8 is a DAG analogue, the effect in seen HEK293 cells would most likely be due to the 
activation of cPKC and/or nPKC, but not an aPKC, as aPKCs require phosphatidylinositols for 




4.1.2 PKC Inhibition Effect on SOICR 
Go6983 increased the occurrence of SOICR in HEK293 cells. This was inconsistent with the 
effect of activation of PKC and contradictory to what I had hypothesised. However, Go6983 
inhibits PKC by binding to the ATP site within the catalytic domain of PKC, preventing PKC 
function. Currently, a Ph.D. project in the lab is looking at the effect of ATP-based kinase 
inhibitors and their effect on RyR2 and SOICR. The results thus far show that many ATP-based 
kinase inhibitors directly activate the RyR2, resulting in SOICR. This suggests that Go6983 
may act on RyR2 in a similar way, making any results obtained using this drug difficult to 
interpret. For this reason, I decided to discontinue the use of Go6983 for the rest of the study. 
In the future, to determine the effect of inhibiting endogenous PKC in HEK293 cells, I could 
use Calphostin C; a potent and selective PKC inhibitor that specifically targets the regulatory 
domain of PKC (Kobayashi et al., 1989). I would expect to see the opposite effect of PKC 
activation, therefore, a decrease in the occurrence of SOICR along with an increase in the 
release threshold for SOICR. 
 
4.1.3 Effect of PKCα Overexpression on SOICR 
Overexpression of PKCα resulted in no change in the release threshold for SOICR, which was 
inconsistent with a small increase in the occurrence of SOICR. I, therefore, reject my hypothesis 
that PKCα would decrease the release threshold for SOICR and increase the SOICR occurrence, 
as an increase in SOICR occurrence is expected to be matched with a decreased release 
threshold for SOICR. However, the very small increase in SOICR occurrence would only 
require a small reduction in the release threshold for SOICR which could have been below the 
sensitivity of my SR Ca2+ measurement assay. Interestingly, PKCα overexpression results in an 
increase in the termination threshold for SOICR. An increase in termination threshold without 
a change in release threshold for SOICR would imply a reduction in the fraction of Ca2+ release, 
however, this possibly would have no effect on the occurrence of SOICR. Though, when the 
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conditions mock, PKCα and PKCα with Dic8 were assessed (Figure 3.8 C), there were no 
differences seen in the termination threshold, therefore, PKCα possibly has no consistent effect 
on termination threshold.  
 
Although Figure 3.4 shows that transfection of PKCα increased the total protein level, it gives 
no indication of misfolded or inactive proteins, therefore, the use of a PKC activity assay could 
be used to determine the activity of PKCα transfection (Murillo-Carretero et al., 2017). 
 
My results showed that PKCα with Dic8 decreased release threshold for SOICR (Figure 3.8 B). 
This result could suggest that Dic8 activates the overexpressed PKCα, allowing for a significant 
reduction in release threshold which would be consistent with the small increase in SOICR 
occurrence with PKCα. Alternatively, it could be that Dic8 results in a decreased release 
threshold for SOICR, regardless of the overexpression of PKCα, which is consistent with the 
increase in the SOICR occurrence seen with Dic8 alone. To confirm if the results shown in 
Figure 3.8 B is Dic8 independent, luminal Ca2+ imaging comparing Dic8 versus vehicle treated 
HEK293 cells would be performed in the future, where the decrease in the release threshold 
would be compared to the decrease release threshold in the Dic8 with PKCα overexpression. 
 
4.1.4 Effect of PKCε Overexpression on SOICR 
Overexpression of PKCε resulted in a reduction in the termination threshold and release 
threshold for SOICR which was consistent with the large increase in the occurrence of SOICR. 
A reduction of the termination threshold means that there is an increase in the amount of Ca2+ 
released during Ca2+ release events (CICR and SOICR), whereas a reduction of the release 
threshold for SOICR means that less Ca2+ within the SR is required to activate RyR2, resulting 
in a SOCIR event. Therefore, I accepted my hypothesis that PKCε can modulate SOICR (the 
RyR2), as the increase in SOICR occurrence was matched with a decreased release threshold 
52 
 
for SOICR. As mentioned in Section 1.3.1, a reduction of the release threshold can lead to a 
SOICR event, therefore, severely increasing the occurrence of arrhythmia (Liu et al., 2017). 
Though the reduction of release threshold for SOICR between PKCε transfection versus mock 
transfected HEK293 cells seems like a small change (~3% decrease), it is consistent with other 
studies that looked at RyR2 mutations, that can cause sudden cardiac death, which showed a 
~9% reduction in the release threshold for SOICR (Liu et al., 2013). 
 
4.2 Proposed Model of Action of PKCε on SOICR 
PKCε results in a reduction of the release threshold and termination threshold, along with an 
increased occurrence of SOICR, however, the molecular interaction that results in these changes 
are unknown. The current literature has led us to the deduction that there are three proposed 
models in which these effects could occur.  
 
4.2.1 PKCε Phosphorylation of RyR2 
Kinases that become overexpressed, such as CaMKII and PKA, can lead to RyR2 
phosphorylation, resulting in the reduction of the release threshold and termination threshold, 
increasing the occurrence of SOICR and the amount of Ca2+ released (Wehrens et al., 2006). 
Transgenic mice that had an acute overexpression of CaMKIIδ resulted in an increase in Ca2+ 
leak (SOICR) as well as an increase in RyR2 phosphorylation at S2809 and S2815 (Kohlhaas 
et al., 2006). I therefore hypothesise that in DM, an increased activity PKCε results in a similar 
fashion to these kinases through the phosphorylation of the RyR2 resulting in a structural 
conformational change, resulting in both the reduction of the release threshold for SOICR, 
thereby increasing Ca2+ leak (SOICR) and a reduction in termination threshold, increasing the 
amount of Ca2+ released. As discussed in Section 1.3.1, if the SR Ca2+ load exceeds this release 
threshold for SOICR, it results in RyR2-mediated Ca2+ release from the SR, where a reduction 
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of the release threshold results in a greater risk of SOICR. When SOICR occurs, the increase 
in cytosolic Ca2+ must then be removed, which can result in arrhythmia as described in Section 
1.3.1. 
 
Figure 4.1 Proposed Model: PKCε Mediated Phosphorylation of RyR2 Linking DM to 
Arrhythmia. 
DM has an increase accumulation of DAG which over activates PKCε. PKCε phosphorylates 
RyR2 resulting in SOICR which leads to arrhythmia.  
 
4.2.2 CaMKII Phosphorylation of RyR2 
Another possibility for the increasing occurrence of SOICR along with the decrease in release 
threshold for SOICR, due to a direct phosphorylation of RyR2 by PKC, could be due to indirect 
phosphorylation of RyR2. PKCε has been shown to be able to activate NADPH Oxidase Type 
2 (NOX2) resulting in reactive oxygen species (ROS) release from the mitochondria, which has 
been described to be able to cause oxidation-activation of CaMKII, resulting in CaMKII 
mediated-phosphorylation the RyR2 resulting in SOICR (Erickson et al., 2008; Ho et al., 2014). 
If in fact the increased synthesis and accumulation of DAG in DM does result in an increase in 
PKCε leading to increased oxidation, this study may support the proposed model that CaMKII 
is the major kinase involved in DM arrhythmogenesis (Erickson et al., 2013). Under basal 
conditions, the CaMKII regulatory domain auto-inhibits the catalytic domain, however, it is 
well established that oxidised CaMKII results in the dissociation of the regulatory domain from 
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the catalytic domain, leading to over-activity of the kinase (Erickson et al., 2008; Erickson et 
al., 2011). Not only can oxidised CaMKII result in an increase in activity, but recent studies 
have also shown that O-linked glycosylation (another modification occurring in diabetes) of 
CaMKII can increase its activity (Erickson et al., 2013).  
 
Figure 4.2 Proposed Model: PKCε Activation of CaMKII Links DM to Arrhythmia. 
DM has an increase accumulation of DAG which over activates PKCε. PKCε activates NOX2 
increase ROS production and release increase CaMKII activation. Hyperglycemic environment 
in DM results in O-linked glycosylation of CaMKII increasing its activation. Hyper activation 
of CaMKII results in phosphorylation of RyR2 allowing for SOICR which leads to arrhythmia.  
 
4.2.3 Oxidation of RyR2 
Oxidation of the RyR2 has been shown to lead to a reduction of the release threshold resulting 
in SOICR, therefore, the increased occurrence of SOICR when there is overexpression of PKCε 
may be due to the activation of NOX2 causing ROS production and release, which then could 





Figure 4.3 Proposed Model: PKCε Mediated Oxidation of RyR2 Links DM to arrhythmia. 
DM has an increase accumulation of DAG which over activates PKCε. PKCε activates NOX2 
increase ROS production. The increase in ROS can lead to oxidation of RyR2 allowing for 
SOICR which leads to arrhythmia.  
 
Overall, I propose that there are three possible models by which PKCε may result in a reduction 
of release threshold along with increased SOICR as seen in my study. To determine the most 
probable mode in which PKCε acts to increase SOICR, overexpression of PKCε with either; 
anti-oxidants to prevent oxidation of CaMKII or RyR2 by reducing ROS, CaMKII inhibitor 
(KN-93) to prevent CaMKII phosphorylation of RyR2 by preventing the dissociation of the 
autoinhibitory regulatory domain from the catalytic domain, or NOX2 inhibitor (Apocynin) to 
prevent ROS production by preventing the assembly of the NOX2 subunits (Birben et al., 2012; 
Pellicena & Schulman, 2014; Qin et al., 2017). If there is still a reduction in release threshold 
with increased SOICR when using an anti-oxidant, KN-93 and Phox-l2, then I would accept 
the proposed model in Figure 4.1. If, however, the use of KN-93 results abolishes the effect, 
PKCε would most likely be due to the activation of CaMKII, therefore, I would accept the 
proposed model in Figure 4.2. If the effect is still seen with KN-93 but abolished or reduced 
significantly with Apocynin, I would accept the proposed model in Figure 4.3. It is also possible 





In my study I used HEK293 cells expressing RyR2 where the dynamics of Ca2+ release and 
entry were directly mediated by RyR2 and SERCA respectively, therefore, changes seen in 
SOICR could directly be linked to RyR2 mediated changes. However, in a cardiomyocyte, there 
are many other Ca2+ handling proteins that can be altered which could affect SOICR or the 
accumulation of Ca2+ within the cytosol. Currently, what is known about PKC role in the 
activity of other Ca2+ handling proteins is that PKCα in heart failure has been shown to 
phosphorylate protein phosphatase 1 (PP1), activating it, resulting in hypophosphorylation of 
PLB, thereby decreasing SERCA function (Braz et al., 2004). The effect of PKC, regardless of 
isoform, on other Ca2+ handling proteins such as LTCC, NCX and Ca2+-ATPase are not yet 
established, therefore, I must interpret results found in future studies on PKC in animal or 
human cardiac tissue with consideration of the multifaceted system. 
 
Due to time constraints, I was unable to complete an ideal suite of experiments. To complete 
my study, it would be prudent to perform the following additional work: 
 
1) Western blot analysis looking at total RyR2, PKCε and GAPDH using cell lysates from 
HEK293 cells transfected with PKCε to confirm transfection efficiency and that PKCε 
does not change RyR2 expression. 
2) Luminal Ca2+ imaging to determine if Dic8 alone reduces the release threshold for 
SOICR, mentioned in Section 4.1.3. 
3) Cytosolic and luminal Ca2+ imaging using Calphostin C to determine the effect of ATP-




4.4 Future Steps 
4.4.1 Cellular Studies 
To determine if the effect of Dic8 was specific to one of the subclasses, the use of a broad 
spectrum nPKC or cPKC (Bisindolylmaleimide) inhibitor could be used along with Dic8 (Hers 
et al., 1999). If the nPKC inhibitor or Bisindolylmaleimide attenuates the increase in SOICR 
seen by Dic8, then it is most likely the subclass being activated with Dic8 resulting in an 
increase in SOICR occurrence. The development of a broad nPKC inhibitor is required. 
 
To confirm my hypothesis that RyR2 phosphorylation by PKC is what results in the decreased 
release threshold and thus the increased SOICR occurrence, western blotting looking at total 
phosphorylation of RyR2 using an antibody that binds specifically to phosphorylated residues 
normalised to total RyR2 would be required. I could then compare RyR2 phosphorylation levels 
between PKCα, PKCε, and mock transfected HEK293 cell lysates. As my results showed a 
decreased release threshold and termination threshold as well as an increase in SOICR 
occurrence with PKCε transfected HEK293 cells, I would expect an increase in total RyR2 
phosphorylation compared to the mock transfected cells, where I would expect to see little/no 
change in total RyR2 phosphorylation due to PKCα. If results show an increase in RyR2 
phosphorylation, the next step would then be to determine the site of phosphorylation. One way 
is to use bioinformatics (software/websites) to predict possibly PKC phosphorylation sites 
within RyR2 that matches the consensus sequence (Bauerova-Hlinkova et al., 2010; Gao et al., 
2010). The presence/ absence of these sites can then be confirmed using mass spectrometry 
(Dephoure et al., 2013). The sites can then be manipulated using site-directed mutagenesis to 
perform functional studies and specific antibodies can be developed that target these sites of 




In many proposed models of RyR2, there is a certain phosphorylation ‘hot spot’ where three 
residues have been proposed to be phosphorylated by PKA, CaMKII, and PKG (Valdivia, 
2012). Due to the intensive research into RyR2 phosphorylation at these sites, HEK293 cell 
models expressing mutant forms of RyR2 have been developed where serine is replaced by 
alanine at the proposed phosphorylation target to prevent phosphorylation (Meng et al., 2007). 
To determine if one of these three sites is a potential site of phosphorylation, the increase of 
SOICR occurrence due to PKCε transfection, would be diminished or abolished when using 
these HEK293 cell mutants with either one, two, or all three sites being altered from serine to 
alanine.  
 
Along with PKCα and PKCε, PKCβ2 and PKCδ have also been shown to be expressed in the 
heart and also have an increased activity or expression in DM (Borghini et al., 1994). Using the 
same experimental design as this study examining the effect of PKCβ2 and PKCδ could give 
further insight into which isoform results in the highest promotion of SOICR, in order to 
propose a potential therapeutic target in DM, as well as if RyR2 phosphorylation is also 
dependent on the subclass rather than the isoform (PKCβ2 and PKCδ are cPKC and nPKC 
respectively). One thing that must be considered is that each isoform may be phosphorylating 
the RyR2 at different rates and at different sites all with different effects making the model yet 
more complicated.  
 
4.4.2 Animal Studies 
Following from cellular studies, the next step would be to determine the effect of PKC mediated 
SOICR in rat cardiomyocytes. Not only have DM rats been shown to have an increased risk of 
arrhythmia, they also show an increase in Ca2+ leak within the cardiomyocytes compared to 
non-DM (Smogorzewski et al., 1998; Movahed et al., 2005; Yaras et al., 2005). For my 
experiment, rat hearts of DM and non-DM would be excised and cardiomyocytes would be 
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isolated using enzymatic digestion. These isolated cardiomyocytes would then be loaded with 
a cytosolic Ca2+ indicator dye, where cytosolic Ca2+ imaging would be performed to determine 
the occurrence of SOICR (Mu et al., 2014). Therefore, my experiment would be to see the effect 
of SOICR in DM rat cardiomyocytes treated with a PKC inhibitor. I would expect that in the 
DM rat cardiomyocytes, PKC inhibition would attenuate the increased occurrence in SOICR, 
reducing the SOICR release similar to that of the non-DM rat. As my study showed that PKCε 
increases SOICR, I would test the effect of PKCε inhibitor peptide that inhibits the translocation 
of the active PKCε.  
 
Functional effects of PKC inhibitors can also be used to see the generation of arrhythmia. DM 
rats experiencing arrhythmogenic events, seen on an electrocardiography would be treated with 
PKC inhibitors, where the occurrence of arrhythmic events would be compared between pre-
treatment and post-treatment. Here I would expect to see a reduction in arrhythmogenic events 
in the post-treatment. 
 
4.5 Summary  
In summary, my results suggest that PKCε causes a reduction in the release threshold and 
termination threshold, thereby resulting in an increase in the occurrence SOICR. The way in 
which PKCε does this may either be through direct phosphorylation of RyR2, indirect 
phosphorylation of RyR2 through the oxidation-activation of CaMKII, or oxidation-activation 
of RyR2. PKCε is not only highly expressed in the heart, but it has increased activation in DM, 
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